Skip to main content

Advertisement

Table 2 Day 7 piperaquine concentrations by adherence status

From: A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission

  Median drug concentration ng/ml [IQR] p value1
Observed intake control group (N = 94)2 128.5 [53.5–189.0] Reference
Non-observed treatment intake (N = 236)3 95.5 [34.9–186.0] 0.051
Self-reported adherence
 Full adherence (N = 215) 107.0 [41.0–192.0] 0.187
 Non-adherence (N = 21) 30.4 [2.9–69.6] < 0.001
Self-reported non-adherence
 Completed two doses (N = 8) 57.8 [3.3–100.7] 0.034
 Completed one dose (N = 11) 36.8 [2.9–60.9] 0.001
 Completed no doses (N = 2) 7.1 [<LLOQ–12.9] 0.017
  1. 1Calculated by the two-sample Wilcoxon rank-sum (Mann-Whitney) test against the observed intake control group. Significant p values are set in italics
  2. 2Ten samples with drug concentration falling below the limit of quantification (<LLOQ), three samples with reports of vomiting within 30 min after drug intake, and one sample with self-reported non-adherence were excluded from the control group
  3. 3Three samples excluded due to improper sample conditions